Who are Cabaletta Bio, Inc.'s main suppliers?

Cabaletta Bio, Inc. (CABA) key suppliers include: CANTOR-FITZGERALD-CO, GUGGENHEIM-SECURITIES-LLC, LONZA, MINARIS, TD-SECURITIES-USA-LLC and 1 more. View the full supplier network at chainsifter.com/chain/CABA.

Who are Cabaletta Bio, Inc.'s major customers?

Cabaletta Bio, Inc. (CABA) key customers include: Gilead Sciences, Inc., Gilead Sciences, Inc., Kyverna Therapeutics, Inc., Myriad Genetics, Inc., Myriad Genetics, Inc. and 5 more. View the full customer network at chainsifter.com/chain/CABA.

What sector is Cabaletta Bio, Inc. in?

Cabaletta Bio, Inc. (CABA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Cabaletta Bio, Inc. Suppliers, Customers & Supply Chain (CABA)

6Suppliers

10Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Cabaletta Bio, Inc. (CABA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships

3Distinct source URLs

9High confidence

0.776Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Cabaletta Bio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CANTOR-FITZGERALD-CO	CANTOR-FITZGERALD-CO	90%	On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgeral…
GUGGENHEIM-SECURITIES-LLC	GUGGENHEIM-SECURITIES-LLC	90%	On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgeral…
LONZA	LONZA	90%	In December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of the Company's cell processing manufacturing partners
MINARIS	MINARIS	90%	In August 2023, and as extended in August 2024, the Company entered into work orders under the Minaris Agreement for Minaris to serve as a cell processing manufacturing partner for the MusCAARTes TM …
TD-SECURITIES-USA-LLC	TD-SECURITIES-USA-LLC	90%	On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgeral…
CLYM	Climb Bio, Inc.	72%	Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candid…

Cabaletta Bio, Inc. Customers

Ticker	Name	Confidence	Evidence
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from CABA graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CABA graph: Reciprocal relationship from GILD g…
GILD	Gilead Sciences, Inc.	72%	ticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report. The risk factors denoted with a "*", if any, are newly added or hav…
KYTX	Kyverna Therapeutics, Inc.	72%	Reciprocal relationship from KYTX graph: Reciprocal relationship from CABA graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CABA graph: Reciprocal relationship from KYTX g…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from CABA graph: and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require a…
MYGN	Myriad Genetics, Inc.	72%	and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require additional discovery research and then preclinical and clinical development. In add…
NVS	Novartis AG	62%	Reciprocal relationship from NVS graph: Reciprocal relationship from CABA graph: Reciprocal relationship from NVS graph: Reciprocal relationship from CABA graph: Reciprocal relationship from NVS grap…
PRESENTATION-CABALETTA-BIO-INC	PRESENTATION-CABALETTA-BIO-INC	62%	disclosures Cash paid for interest $ 877 $ 208 Right-of-use assets obtained in exchange for finance lease obligations $ 4,841 $ 14,930 The accompanying notes are an integral part of these unaudited c…
TYCHO-THERAPEUTICS-INC	TYCHO-THERAPEUTICS-INC	62%	disclosures Cash paid for interest $ 877 $ 208 Right-of-use assets obtained in exchange for finance lease obligations $ 4,841 $ 14,930 The accompanying notes are an integral part of these unaudited c…
USA-LLC	USA-LLC	62%	of our research and development activities, which are directed toward identifying and developing product candidates. We expense all research and development costs in the periods in which they are inc…
WUXI-ADVANCED-THERAPIES-INC	WUXI-ADVANCED-THERAPIES-INC	62%	ay 2026. Based on the safety profile observed at the lowest dose, multiple additional patients have been enrolled at a higher dose cohort in the RESET-PV trial ® and longer-term data at the higher do…

Cabaletta Bio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CABA-DEBT-8446	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2018-12-31.
CABA-DEBT	Debt stack $26.4M	90%	Market cache reports total debt of $26.4M.
CABA-DEBT-16538	Warrants outstanding: 3090190	90%	xbrl warrant detail from xbrl 2026-03-31.

Cabaletta Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cabaletta Bio, Inc..

Cabaletta Bio, Inc. Ownership

Holder	Name	Confidence	Evidence
CABA-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME	T. Rowe Price Investment Management, Inc.	90%	13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 112 tracked holders.

Cabaletta Bio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BIAF	bioAffinity Technologies, Inc.	100.00	2
GILD	Gilead Sciences, Inc.	100.00	1	['customer']
ELVN	Enliven Therapeutics, Inc.	100.00	2
ATYR	aTyr Pharma, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	2
CLYM	Climb Bio, Inc.	100.00	1	['supplier']
CAH	Cardinal Health, Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CGEM	Cullinan Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ALMS	Alumis Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2

Cabaletta Bio, Inc. Supply Chain